Michelle Parra
Family · Fort Wayne, INNPI 1679805048
Payments from drug & device makers
Across 234 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$891
- Supernus Pharmaceuticals, Inc.$580
- AbbVie$411
- Alkermes, Inc.$387
- Teva Pharmaceuticals USA, Inc.$293
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$288
- plus $2K from 15 others
What the payments were for
- Food & beverage$4,25496%
- Education$1564%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 44 | $891 |
| Supernus Pharmaceuticals, Inc. | 36 | $580 |
| AbbVie | 28 | $411 |
| Alkermes, Inc. | 18 | $387 |
| Teva Pharmaceuticals USA, Inc. | 13 | $293 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $288 |
| Lundbeck LLC | 18 | $288 |
| Otsuka America Pharmaceutical, Inc. | 7 | $233 |
| Corium, LLC | 19 | $221 |
| Neurocrine Biosciences, Inc. | 7 | $174 |
| Indivior Inc. | 5 | $104 |
| Biogen | 4 | $94 |
| E.r. Squibb & Sons, L.L.C. | 4 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Tris Pharma Inc | 4 | $66 |
| Johnson & Johnson | 3 | $63 |
| Axsome Therapeutics, Inc. | 3 | $56 |
| Gilead | 2 | $40 |
| Ironshore Pharmaceuticals Inc. | 1 | $24 |
| Neos Therapeutics, LP | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$122
How this compares
$4,410 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 23 | $178,677 |
| Invega SustennaPaliperidone Palmitate | 58 | $175,134 |
| RexultiBrexpiprazole | 104 | $158,788 |
| Abilify MaintenaAripiprazole | 55 | $156,891 |
| VraylarCariprazine Hcl | 86 | $132,349 |
| CaplytaLumateperone Tosylate | 41 | $69,457 |
| FanaptIloperidone | 14 | $45,843 |
| AustedoDeutetrabenazine | 17 | $40,480 |
| Lurasidone Hcl | 158 | $23,540 |
| Paliperidone ErPaliperidone | 38 | $14,371 |
| Aripiprazole | 235 | $12,019 |
| TrintellixVortioxetine Hydrobromide | 21 | $9,476 |
| Buspirone Hcl | 529 | $7,397 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 152 | $6,777 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 207 | $6,691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $233 | $315,678159 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $174 | $178,67723 claims |
| Johnson & JohnsonInvega Sustenna | $63 | $175,13458 claims |
| AbbVieVraylar | $411 | $132,34986 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $288 | $69,45741 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $293 | $40,48017 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $69 | $15,77937 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.
Other family in Fort Wayne
- Justin BrownFort Wayne$142K
- Tracy JohnsonFort Wayne$68K
- Grant BlauveltFort Wayne$28K
- Benjamin GiarmoFort Wayne$21K
- Katarzyna SedlaczekFort Wayne$20K
- Brandy DantzerFort Wayne$18K
- Catherine RobertsFort Wayne$13K
- Adam ZuberFort Wayne$13K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.